Lymphoma Clinical Studies

Some of the many Cancer and Blood Disorders research opportunities available related to lymphoma are listed below. Select a study to review a brief description and requirements. Parents or guardians of children who might be eligible are encouraged to inquire about enrollment. Contact information is provided at the end of each study.

Please note that Pilot and Phase I studies are the most experimental and should be considered only after other treatments or trials have been attempted without success.

Thank you for exploring these opportunities and helping us to find cures and prevent childhood disease.

Clinical Studies


Acute Lymphoblastic Leukemia and B-Lineage Lymphoma Treatment via Risk-Adapted Chemotherapy – Phase III

Risk-Adapted Chemotherapy in Treating Younger Patients with Newly Diagnosed Standard-Risk B-Acute Lymphoblastic Leukemia or localized B-Lineage Lymphoblastic Lymphoma

Read more

Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Treatment using Palbociclib and Chemotherapy – Phase I

AIVN18P1: Study of Palbociclib, a CDK 4/6 Inhibitor, in Combination with Chemotherapy in Children with Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Read more

Anaplastic Large Cell Lymphoma Treatment with Brentuximab Vedotin or Crizotinib – Phase II

Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma

Read more

Hodgkin Lymphoma Treatment with Brentuximab Vedotin – Phase III

Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents

Read more

M0 Medulloblastoma Treatment in Very Young Children – Phase I

Study of Eribulin Mesylate, a Novel Microtubule Targeting Chemotherapeutic Agent, in Children with Refractory or Recurrent Solid Tumors including Lymphomas

Read more

Non-Hodgkin Lymphoma or B-Cell Leukemia Evaluation of Rituximab– Phase II/III

Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma or Mature B-cell Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients

Read more

Solid Tumor and Lymphoma Treatment with PI3K – Phase I/II

ADVL1721: Study of PI3K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refractory Solid Tumors or Lymphoma

Read more

Solid Tumor Treatment with MLN4924, Temozolomide & Irinotecan

ADVL1615: Study of Pevonedistat (MLN4924), a NEDD8-Activating Enzyme Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors

Read more

Solid Tumor Treatment with Selinexor – Phase I

ADVL1414: Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors Including CNS Tumors

Read more

T-cell Lymphoblastic Leukemia and Lymphoma Treatment with Bortezomib – Phase III

Bortezomib on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Read more